TARGET AUDIENCE
This educational activity is intended for members of the hematology care team, including physicians, NPs, and PAs.

PROGRAM OVERVIEW
As new therapies expand the possibilities for managing immune thrombocytopenia (ITP), treatment decisions are becoming increasingly complex. Beyond platelet counts and clinical response, what should guide treatment choices, and how can emerging approaches better reflect patients’ priorities, daily experiences, and long-term goals? In this discussion, a patient and their clinician will share their perspectives on the evolving approach to ITP management, the needs that remain unmet, and opportunities to improve care as new treatment options become available.

Upon completion of this activity, the learners should be able to:

• Explain how emerging targeted therapies for ITP address the immunopathogenesis of the disease
• Outline changes to clinical practice which may be necessary to integrate new and emerging therapies for ITP

FACULTY
Adam Cuker, MD, MS
Director, Penn Comprehensive and Hemophilia Thrombosis Program
Professor of Medicine (Hematology-Oncology)
Hospital of the University of Pennsylvania
Professor of Medicine in Pathology and Laboratory Medicine
Philadelphia, PA

Cass Benedetto
Patient Guest

PLANNING COMMITTEE
Adam Cuker, MD, MS
Director, Penn Comprehensive and Hemophilia Thrombosis Program
Professor of Medicine (Hematology-Oncology)
Hospital of the University of Pennsylvania
Professor of Medicine in Pathology and Laboratory Medicine
Philadelphia, PA

Michele P. Lambert, MD, MSTR
Medical Director
Special Coagulation Laboratory Attending Physician
Division of Hematology at Children's Hospital of Philadelphia
Philadelphia, PA

Shiying Siliva Zheng, BSc (Med), MBBS, PhD
Hematologist
Senior Conjoint Lecturer
St. George Hospital
University of NWW
Sydney, Australia

Melissa Glasner, MSc
Medical Writer
The France Foundation
Old Lyme, CT

This activity is jointly provided by The France Foundation and the ISTH.

ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by The France Foundation and the ISTH. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

PHYSICIAN CREDIT DESIGNATION
The France Foundation designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other health care professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all individuals in a position to control the content of this educational activity must disclose all relevant financial relationships with ineligible companies. All identified conflicts of interest are reviewed and mitigated to ensure independence, objectivity, balance, and scientific rigor.

This activity adheres to generally accepted standards of scientific integrity, including requirements for appropriate study design, data collection, and analysis. The organizers of this activity are committed to providing high-quality CME/CE that promotes improvements in health care and serves the needs of learners and not commercial interests. When applicable, collaborating partners participate in the disclosure and mitigation process.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

Faculty for this educational activity are required to disclose when a therapy or procedure being discussed is off-label, unlabeled, experimental or investigational, and to note any limitations of the data presented (e.g., preliminary findings, ongoing research, or expert opinion).

Some faculty may discuss uses of pharmaceutical agents or devices that are not included in U.S. Food and Drug Administration–approved labeling. These discussions are provided solely for educational purposes and should not be construed as a recommendation for any particular use. Learners are encouraged to review full prescribing information for products discussed.

This activity is intended for health care professionals for educational purposes only. The content reflects information available at the time of development and may not represent the most current evidence, regulatory status, or prescribing information. Participants should consult current package inserts, clinical guidelines, and institutional policies before prescribing medications or making clinical decisions.

This activity has been planned and implemented in compliance with applicable accreditation standards to ensure that content is fair, balanced, evidence-based, and free of commercial bias.

This activity is supported by an independent medical educational grant from Novartis.